Search

Your search keyword '"Iveson, Tim"' showing total 125 results

Search Constraints

Start Over You searched for: Author "Iveson, Tim" Remove constraint Author: "Iveson, Tim"
125 results on '"Iveson, Tim"'

Search Results

1. JAK/STAT3 represents a therapeutic target for colorectal cancer patients with stromal-rich tumors

2. Single-cell AI-based detection and prognostic and predictive value of DNA mismatch repair deficiency in colorectal cancer

3. Standardizing data collection in adjuvant colon cancer trials: A consensus project from the IDEA and ACCENT international consortia and national experts

4. Multiplex analysis of intratumoural immune infiltrate and prognosis in patients with stage II–III colorectal cancer from the SCOT and QUASAR 2 trials: a retrospective analysis

5. A population-scale temporal case–control evaluation of COVID-19 disease phenotype and related outcome rates in patients with cancer in England (UKCCP)

6. Vaccine effectiveness against COVID-19 breakthrough infections in patients with cancer (UKCCEP): a population-based test-negative case-control study

8. Second-line FOLFOX chemotherapy versus active symptom control for advanced biliary tract cancer (ABC-06): a phase 3, open-label, randomised, controlled trial

10. The Glasgow Microenvironment Score associates with prognosis and adjuvant chemotherapy response in colorectal cancer

11. Capecitabine compared with observation in resected biliary tract cancer (BILCAP): a randomised, controlled, multicentre, phase 3 study

12. Prognostic and Predictive Value of Immunoscore in Stage III Colorectal Cancer: Pooled Analysis of Cases From the SCOT and IDEA-HORG Studies.

14. Accounting for intensity variation in image analysis of large-scale multiplexed clinical trial datasets

15. Accounting for intensity variation in image analysis of large‐scale multiplexed clinical trial datasets.

16. COVID-19: Third dose booster vaccine effectiveness against breakthrough coronavirus infection, hospitalisations and death in patients with cancer: A population-based study

17. Gemcitabine and capecitabine with or without telomerase peptide vaccine GV1001 in patients with locally advanced or metastatic pancreatic cancer (TeloVac): an open-label, randomised, phase 3 trial

18. Systemic chemotherapy with or without cetuximab in patients with resectable colorectal liver metastasis: the New EPOC randomised controlled trial

19. Critical research gaps and recommendations to inform research prioritisation for more effective prevention and improved outcomes in colorectal cancer

20. Vaccine effectiveness against COVID-19 breakthrough infections in patients with cancer (UKCCEP): a population-based test-negative case-control study

21. Long-Term Outcomes and Exploratory Analyses of the Randomized Phase III BILCAP Study

23. Second-line FOLFOX chemotherapy for advanced biliary tract cancer – Authors' reply

24. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer

25. Association of SARS-CoV-2 Spike Protein Antibody Vaccine Response With Infection Severity in Patients With Cancer: A National COVID Cancer Cross-sectional Evaluation

28. Long Term Outcomes and Exploratory Analyses of the Randomised Phase 3 BILCAP Study

29. Patients’ Preferences for 3 Months vs 6 Months of Adjuvant Chemotherapy for Colon Cancer

30. The Glasgow Microenvironment Score associates with prognosis and adjuvant chemotherapy response in colorectal cancer

31. Histological phenotypic subtypes predict recurrence risk and response to adjuvant chemotherapy in patients with stage III colorectal cancer

32. FOLFOX as Second-Line Chemotherapy for Advanced Biliary Tract Cancer

33. Patterns of Recurrence After Resection of Pancreatic Ductal Adenocarcinoma: A Secondary Analysis of the ESPAC-4 Randomized Adjuvant Chemotherapy Trial

34. Patterns of Recurrence After Resection of Pancreatic Ductal Adenocarcinoma : A Secondary Analysis of the ESPAC-4 Randomized Adjuvant Chemotherapy Trial

35. Single-cell AI-based detection and prognostic and predictive value of DNA mismatch repair deficiency in colorectal cancer

40. Patterns of progression, treatment of progressive disease and post-progression survival in the New EPOC study

42. A randomised, open-label phase II trial of afatinib versus cetuximab in patients with metastatic colorectal cancer

43. Add-Aspirin trial: A phase III, double blind, placebo-controlled, randomized trial assessing the effects of aspirin on disease recurrence and survival after primary therapy in common nonmetastatic solid tumors.

44. Predictive cytokine biomarkers for survival in patients with advanced pancreatic cancer randomized to sequential chemoimmunotherapy comprising gemcitabine and capecitabine (GemCap) followed by the telomerase vaccine GV1001 compared to concurrent chemoimmunotherapy in the TeloVac phase III trial.

45. Patterns of progression, treatment of progressive disease, and postprogression survival in the new EPOC study.

46. Analysis of progression-free survival in the new EPOC study in an “all wild-type” population.

47. Outcome of second-line chemotherapy for biliary tract cancer

48. Quality of life, long-term survivors and long-term outcome from the ABC-02 study.

49. Longitudinal quality of life and quality adjusted survival in a randomised controlled trial comparing six months of bolus fluorouracil/leucovorin vs. twelve weeks of protracted venous infusion fluorouracil as adjuvant chemotherapy for colorectal cancer

50. Multiplex analysis of intratumoural immune infiltrate and prognosis in patients with stage II–III colorectal cancer from the SCOT and QUASAR 2 trials: a retrospective analysis.

Catalog

Books, media, physical & digital resources